New Alzheimer's Treatment: Anavex's Blarcamesine Success
Anavex Life Sciences Reports Promising Results for Alzheimer's Treatment From its Phase IIb/III study on blarcamesine (ANAVEX®2-73), a medication for early Alzheimer's disease (AD), Anavex Life Sciences Corp. (Nasdaq: AVXL) has reported encouraging findings. Leading neurology specialist Dr. Marwan Noel Sabbagh delivered the data at the 2024 Alzheimer's Association International Conference (AAIC). Taken once daily, blarcamesine has shown great promise in halting the
Continue Reading